Very cheap Sp at this level, page-7

I think it likely the Co. will get FDA approval for a label change based on these results, and that might broaden it's use. It will certainly do no harm.

But out of 200 or so patients it would appear that not a single one was down-staged to have surgical resection or transplant and I think that will raise questions about how well the SIRT arm was managed. It's possible that better management would have had a better result.

Things can still improve from here in the short term.